Certificate Under Reg. 40(9) For The Half Year Ended September 30, 2018
Certificate under Reg. 40(9) for the half year ended September 30, 201817-10-2018
17-10-2018
Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Zoheb SayaniDesignation :- Company Secretary and Compliance Officer13-10-2018
Disclosure of Voting results of EGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Vanta Bioscience Ltd has informed BSE regarding the details of Voting results of EGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here01-10-2018
Outcome Of EGM Dated September 29, 2018
Proceedings, Voting Results and Scrutinizers'' Report for EGM dated September 29, 201830-09-2018
Corrigendum To Notice Of EGM Scheduled On September 29, 2018
Corrigendum to Notice Of EGM scheduled on September 29, 201828-09-2018
Outcome of Board Meeting
We wish to inform you that the Board Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses: 1. The Board approved the preferential issue of upto 13,74,000 equity shares of Rs. 10/- each at a premium of Rs.75/- each to promoters and non-promoters subject to the approval of the shareholders and BSE Ltd. (List annexed)...01-09-2018
Board Meeting Intimation for Preferential Allotment Of Equity Shares And Other Matters
VANTA BIOSCIENCE LTDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2018 ,inter alia, to consider and approve 1. Raising of capital through preferential allotment of equity shares subject to the requisite approvals from shareholders and BSE Ltd 2. To discuss any other matter as may be decided by the Board....27-08-2018
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Vanta Bioscience Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here22-08-2018
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 2nd Annual General Meeting, Voting Results and Scrutinizers'' Report21-08-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are happy to announce that Vanta Bioscience Limited (Scrip Code 540729), which is in the business of pre-clinical services, announced its foray into Clinical Research through a 100% subsidiary. The clinical research business will begin contributing to the top-line in the last quarter of the current financial year. The Company is projecting to add a revenue of Rs.250 crores in the fifth year through clinical research services. In this regards, please find enclosed a Press Release.30-07-2018